Literature DB >> 8583854

Evolution of the management of hydrocephalus associated with acoustic neuroma.

M D Atlas1, J R Perez de Tagle, J A Cook, J P Sheehy, P A Fagan.   

Abstract

The management of hydrocephalus in association with a cerebellopontine angle tumor is controversial. There is a widely held belief that initial therapy should always be directed toward treatment of hydrocephalus before definitive surgery. The potential problems of cerebrospinal fluid (CSF) shunting and drainage have to led to an evolution in the management of hydrocephalus at St. Vincent's Hospital. There is growing evidence that complete removal of cerebellopontine angle tumors will result in resolution of hydrocephalus without requiring other methods of CSF decompression. The authors present their experience of 14 patients with hydrocephalus found in a recent series of 104 consecutive cases of acoustic neuroma. This study has detected a significant correlation between hydrocephalus and increasing tumor size (P = .0234). The mean tumor size in this series was 3.8 cm. The series has also demonstrated that successful. safe, and complete tumor removal can be achieved without CSF drainage before surgery.

Entities:  

Mesh:

Year:  1996        PMID: 8583854     DOI: 10.1097/00005537-199602000-00018

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  8 in total

Review 1.  Vascular hyperpermeability as a hallmark of phacomatoses: is the etiology angiogenesis comparable with mechanisms seen in inflammatory pathways? Part I: historical observations and clinical perspectives on the etiology of increased CSF protein levels, CSF clotting, and communicating hydrocephalus: a comprehensive review.

Authors:  Yosef Laviv; Burkhard S Kasper; Ekkehard M Kasper
Journal:  Neurosurg Rev       Date:  2017-03-07       Impact factor: 3.042

2.  The role of external ventricular drainage for the management of posterior cranial fossa tumours: a systematic review.

Authors:  Pasquale Anania; Denise Battaglini; Alberto Balestrino; Alessandro D'Andrea; Alessandro Prior; Marco Ceraudo; Diego Criminelli Rossi; Gianluigi Zona; Pietro Fiaschi
Journal:  Neurosurg Rev       Date:  2020-06-03       Impact factor: 3.042

3.  Prevalence of hydrocephalus in 157 patients with vestibular schwannoma.

Authors:  Jeffrey M Rogg; S H Ahn; G A Tung; S E Reinert; G Norén
Journal:  Neuroradiology       Date:  2005-05-11       Impact factor: 2.804

4.  Communicating hydrocephalus and vestibular schwannomas: etiology, treatment, and long-term follow-up.

Authors:  Qasim Al Hinai; Anthony Zeitouni; Denis Sirhan; David Sinclair; Denis Melancon; John Richardson; Richard Leblanc
Journal:  J Neurol Surg B Skull Base       Date:  2013-02-07

Review 5.  Characteristics and management of hydrocephalus associated with vestibular schwannomas: a systematic review.

Authors:  Paolo di Russo; Arianna Fava; Alberto Vandenbulcke; Akinori Miyakoshi; Michihiro Kohno; Alexander I Evins; Vincenzo Esposito; Roberta Morace
Journal:  Neurosurg Rev       Date:  2020-04-07       Impact factor: 3.042

6.  Removal of large acoustic neurinomas (vestibular schwannomas) by the retrosigmoid approach with no mortality and minimal morbidity.

Authors:  I Yamakami; Y Uchino; E Kobayashi; A Yamaura; N Oka
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-03       Impact factor: 10.154

7.  Hydrocephalus Associated with Large Vestibular Schwannoma: Management Options and Factors Predicting Requirement of Cerebrospinal Fluid Diversion after Primary Surgery.

Authors:  A R Prabhuraj; Nishanth Sadashiva; Santhosh Kumar; Dhaval Shukla; Dhananjaya Bhat; Bhagavatula Indira Devi; Sampath Somanna
Journal:  J Neurosci Rural Pract       Date:  2017-08

8.  Characteristics and management of hydrocephalus in adult patients with cerebellar glioblastoma: lessons from a French nationwide series of 118 cases.

Authors:  Luc Bauchet; Jacques Guyotat; Thiébaud Picart; Chloé Dumot; David Meyronet; Johan Pallud; Philippe Metellus; Sonia Zouaoui; François Ducray; Isabelle Pelissou-Guyotat; Moncef Berhouma
Journal:  Neurosurg Rev       Date:  2021-07-01       Impact factor: 3.042

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.